Financial Performance - The total operating revenue for the reporting period was approximately ¥339.38 million, a decrease of 15.75% compared to the previous year[3] - The net profit attributable to shareholders was approximately ¥36.58 million, down 4.08% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥35.50 million, an increase of 12.59% year-on-year[3] - The basic earnings per share were ¥0.21, a decrease of 4.55% compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were approximately ¥483.38 million, a slight increase of 0.05% year-on-year[4] - Shareholders' equity attributable to the company was approximately ¥391.14 million, an increase of 7.85% year-on-year[4] Operational Challenges - The decline in operating revenue was primarily due to disruptions in the supply chain caused by recurring domestic COVID-19 outbreaks and geopolitical tensions[5] Financial Data Caution - The company emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[6] - The final data will be disclosed in the company's 2022 annual report[6] Profitability - The company's gross profit margin slightly increased due to effective cost control and exchange rate gains despite a decline in revenue[5]
鹿得医疗(832278) - 2022 Q4 - 年度业绩